Terapevt Arkh
-
Comparative Study
[Changes in hemostasis system in patients with hereditary thrombophilia caused by mutation of blood coagulation factor V ( factor V Leiden)].
To study the incidence of mutation of Leyden's factor V in patients with venous thrombosis and the hemostatic system in carrier of this genetic defect. ⋯ Detection of signs of hypercoagulation in patients with inherited thrombophilia at recovery in carriers of Leyden's factor V without clinical manifestations of thrombosis shows it necessary to make a particularly careful monitoring of the hemostatic system in these subjects. This is especially important for hypercoagulation-predisposing situations, such as pregnancy, surgical interventions, long-term immobilization, use of contraceptives, etc. when preventive measures may be used to prevent thrombotic events.
-
To study etiology, clinico-laboratory characteristics and early prognosis of reactive arthritis developing after respiratory infections (priReA). ⋯ In young patients with early ReA respiratory etiology is observed more frequently than urogenital and enterocolitic ones. Compared to other kinds of ReA, priReA demonstrates some genetic, clinical and prognostic peculiarities.
-
To characterize relationship between prevalence of ankylosing spondylarthritis (ASA) and incidence rate of HLA-B27 in genotypically different ethnic groups of Russia with interpolation of the results to other populations. ⋯ In most world populations prevalence of ASA correlates with population frequency HLA-B27 though in some ethnic groups this correlation is absent. Consequently, ASA is genetically heterogenous.
-
To examine present-day peculiarities of reactive arthritis (ReA) and effects of chlamydial infection on ReA clinical manifestations. ⋯ At present, ReA is characterized by the following most typical features: polymorphism of clinical symptoms at the disease onset, predominance of polyarticular variant of articular involvement at the advanced stage of ReA, high incidence of extraarticular manifestations. The factor analysis shows that clinical picture of ReA is established by "activity" and "unfavourable course" factors.
-
To study the effects of F(ab')2 fragments of the monoclonal antibody (monAB) FRaMon against glycoproteins (GP) IIb-IIIa on platelet aggregating activity in vitro and after injection to healthy volunteers. ⋯ F(ab')2 fragments of monAB FRaMon effectively inhibited aggregating ability both in vitro and after injection to healthy volunteers and could be suggested as a basis for development of a new GP IIb-IIIa antagonist.